Verona Pharma Announces US FDA Approval of Ohtuvayre TM (ensifentrine) Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodi

Announces US FDA Approval of OhtuvayreTM (ensifentrine)

indicated for the maintenance treatment of COPD allowing for broad use in COPD patients

COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects

tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST

N.C., June 26, 2024 - Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma" or the "Company"), announces

the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive

pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the

maintenance treatment of COPD in more than 20 years.

first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 ("PDE3 and PDE4") that

combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is delivered directly to the lungs through

a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination.

of Ohtuvayre is a significant advance in COPD care, and we believe Ohtuvayre's novel profile can change the treatment paradigm

for COPD," said David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma. "We plan to launch

Ohtuvayre in the third quarter 2024, ensuring Ohtuvayre is available to help the millions of patients who still experience daily COPD

MD, Associate Professor in the Division of Pulmonary, Allergy, and Critical Care Medicine at the University of Alabama Birmingham, commented:

"In my experience, despite maintenance therapy, most patients report grappling with daily symptoms, including breathlessness and

persistent coughing. COPD has a significant impact on both mortality and morbidity in the US, and until today, innovation in inhaled

treatment modalities has been limited to combinations of existing treatment classes for over two decades. Ohtuvayre, as a first-in-class

PDE3 and PDE4 inhibitor, offers a needed, unique approach and is an important advance in the treatment of COPD."

of Ohtuvayre was based on extensive data including the Phase 3 ENHANCE trials, the results of which were published in the American

Journal of Respiratory and Critical Care Medicine. In the ENHANCE trials, Ohtuvayre demonstrated clinical benefits both alone

and when used with other maintenance therapies. Ohtuvayre was well-tolerated in a broad population of subjects with moderate to severe

fully staffed to launch and expects Ohtuvayre to be available in the third quarter 2024 through an exclusive network of accredited specialty

host an investment community conference call at 8:30 a.m. EDT / 1:30 p.m. BST on Thursday, June 27, 2024 to discuss the US approval of

Ohtuvayre. To participate, please dial one of the following numbers and ask to join the Verona Pharma call:

will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the

audio replay will be available for 90 days.

first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities

in one molecule. Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE ("Ensifentrine as a Novel inHAled

Nebulized COPD thErapy") for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating

statistically significant and clinically meaningful improvements in lung function. A fixed-dose combination of ensifentrine and glycopyrrolate,

a LAMA, is currently under development for the maintenance treatment of COPD. Ensifentrine has potential applications for development

in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases.

Ohtuvayre is a prescription medicine

used to treat COPD in adults. COPD is a chronic (long-term) lung disease that includes chronic bronchitis, emphysema, or both.

What is the most important information

I should know about Ohtuvayre?

Ohtuvayre can cause serious side effects,

Do not use Ohtuvayre

to treat sudden breathing problems. Always have a rescue inhaler with you.

Who Should Not use Ohtuvayre?

Do not use Ohtuvayre if you have had

an allergic reaction to ensifentrine or any of the ingredients in Ohtuvayre.

What should I tell my healthcare

provider before using Ohtuvayre?

Ohtuvayre, tell your healthcare professional if you have or have had a history of mental health problems including depression and suicidal

behavior; have liver problems; are pregnant or plan to become pregnant; are breastfeeding. It is not known if Ohtuvayre may harm your

unborn baby. It is not known if the medicine in Ohtuvayre passes into your breast milk and if it can harm your baby.

Tell your healthcare

provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

most common side effects of Ohtuvayre?

side effects of Ohtuvayre include back pain, high blood pressure, bladder infection and diarrhea.

the possible side effects of Ohtuvayre. Call your doctor for medical advice about side effects. You may report side effects to FDA at

does not include all the information about Ohtuvayre and is not meant to take the place of a discussion with your healthcare provider

about your treatment.

information, please see the full Prescribing Information, including the Patient Information Leaflet.

to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

pulmonary disease ("COPD") refers to a group of diseases that cause airflow blockage and breathing-related problems, such

as emphysema and chronic bronchitis. More than 390 million people worldwide are living with COPD, and more than 8.6 million Americans

are treated chronically1-2. Symptoms include increased shortness of breath, frequent coughing (with and without mucus), wheezing,

tightness in the chest and unusual tiredness. Approximately 50% of COPD patients experience almost daily symptoms3. There

is no cure for COPD and despite available treatment options, it is the third leading cause of death globally.

D, et al. Lancet Respir Med. 2022;10(5):447-458

IQVIA Ensifentrine Market Research

2022 COPD Patient Survey

a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases

with significant unmet medical needs, including COPD, non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory

diseases. For more information, please visit www.veronapharma.com.

For further information

Forward-Looking Statements

release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All

statements contained in this press release other than statements of historical fact should be considered forward-looking statements.

Words such as "anticipate," "believe," "plan," "expect," "intend,"

"may," "potential," "prepare," "possible" and similar words and expressions are

intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements

regarding the potential benefits, efficacy, and approval of our drug Ohtuvayre, including, but not limited to, statements relating

to the potential to change the treatment paradigm for COPD patients, the

anticipated timing of commercial availability and our ability to successfully market and sell Ohtuvayre.

These forward-looking

statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and

unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially

different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following:

our limited operating history; our need for additional funding to complete development and commercialization of Ohtuvayre which may not

be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; our reliance on the success

of Ohtuvayre, our only commercial product; our reliance on third-party manufacturers and suppliers; the efficacy of Ohtuvayre compared

to competing drugs; our ability to successfully commercialize Ohtuvayre; serious adverse, undesirable or unacceptable side effects associated

with Ohtuvayre which could adversely affect our ability to commercialize Ohtuvayre; failure to develop Ohtuvayre for additional indications,

alternate delivery methods, or as a combination therapy; failure to obtain approval for and commercialize Ohtuvayre in multiple major

pharmaceutical markets; lawsuits related to patents covering Ohtuvayre and the potential for our patents to be found invalid or unenforceable;

lawsuits related to our licensing of patents and know-how from third parties for the commercialization of Ohtuvayre; changes in our tax

rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments that could affect our

profitability, and audits by tax authorities that could result in additional tax payments for prior periods; and our vulnerability to

natural disasters, global economic factors, geo-political actions and unexpected events, including health epidemics or pandemics. These

and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the period

ended March 31, 2024 filed with the Securities and Exchange Commission ("SEC") on May 10, 2024, and our other reports filed

with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press

release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect

to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events

cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing